The Affiliated Hospital Of Xuzhou Medical University
Clinical trials sponsored by The Affiliated Hospital Of Xuzhou Medical University, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Engineered immune cells take on autoimmune diseases Results expected Sep 2026 (estimated)
- New triple attack on advanced cancers enters human testing Results expected Dec 2026 (estimated)
- Experimental CAR-T therapy takes on stubborn muscle weakness Results expected Jun 2027 (estimated)
- New drug cocktail aims to outsmart aggressive blood cancer Results expected Jun 2027 (estimated)
-
Cholesterol drug tested to stop stroke worsening
Disease control CompletedThis study tested whether giving the cholesterol-lowering drug evolocumab within 24 hours after clot-busting treatment (thrombolysis) can prevent early neurological decline in people with acute ischemic stroke. 132 participants were randomly assigned to receive evolocumab plus st…
Phase 2 • Sponsor: The Affiliated Hospital of Xuzhou Medical University • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug combo after stroke shows promise in preventing early decline
Disease control CompletedThis study tested whether giving a powerful cholesterol-lowering drug (evolocumab) within 6 hours after a stroke procedure (thrombectomy) could prevent early neurological worsening. 60 adults with large-vessel stroke were randomly assigned to receive either the drug plus standard…
Phase 4 • Sponsor: The Affiliated Hospital of Xuzhou Medical University • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC